Voices
Miguel Gonzalez Velez: Divarasib Shows Potential as a Best-in-Class KRAS G12C Inhibitor
Miguel Gonzalez Velez/regionalcancercare.org

Miguel Gonzalez Velez: Divarasib Shows Potential as a Best-in-Class KRAS G12C Inhibitor

Miguel Gonzalez Velez, Medical Oncologist at John Theurer Cancer Center, Hackensack University Medical Center, shared a post on LinkedIn:

“Genentech‘s divaribasib, has shown superior results in clinical trials Compared to SOC KRAS G12C. Having the potential best in class allows direct head to head comparison.

Learn more about this promising development.”

Other articles featuring Miguel Gonzalez Velez on OncoDaily.

cancer clinical trials Divarasib Genentech Miguel Gonzalez Velez OncoDaily Oncology